The prevention, diagnosis, and management of infectious disease in transplantation are
major contributors to improved outcomes in organ transplantation. The risk of serious …

Immunosuppressive agents are commonly used in the nephrologist's practice in the
treatment of autoimmune and immune-mediated diseases and transplantation, and they are …

These guidelines cover the care of patients from the period following kidney transplantation
until the transplant is no longer working or the patient dies. During the early phase …

Post-transplant lymphoproliferative diseases (PTLD) are heterogeneous lymphoid disorders
ranging from indolent polyclonal proliferations to aggressive lymphomas that complicate …

Epstein–Barr virus (EBV) is an important pathogen in recipients of solid organ transplants
(SOT). Infection with EBV manifests as a spectrum of diseases/malignancies ranging from …

In kidney transplant recipients, cancer is one of the leading causes of death with a
functioning graft beyond the first year of kidney transplantation, and malignancies account …

Post-transplant lymphoproliferative disorders (PTLDs) are a group of conditions that involve
uncontrolled proliferation of lymphoid cells as a consequence of extrinsic …

Outcomes of kidney transplantation, in terms of graft and patient survival, have improved
over the past few decades, partly as a result of the introduction of new immunosuppressive …

Post‐transplant lymphoproliferative disorder (PTLD) is rare and heterogeneous lymphoid
proliferations that occur as a result of immunosuppression following solid organ transplant …

Malignancy is the second most common single cause of death observed in organ transplant
recipients. The excess cancer risk is related to intensity and duration of immunosuppressive …